Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Projected Market Size and Growth Rates for the Roxadustat Market From 2025 To 2029?#_x000D_

In recent years, the roxadustat market has witnessed robust growth. It is projected to increase from $6.44 billion in 2024 to $6.86 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.5%. This expansion during the historic period is linked to factors such as regulatory authorization in major markets, favorable clinical trial outcomes, a rising incidence of chronic kidney disease, heightened cognizance of anemia management, and governmental backing for anemia therapies._x000D_

_x000D_

The roxadustat market size is forecasted to experience robust growth in the forthcoming years. It’s projected to expand to $8.95 billion in 2029, with a compound annual growth rate (CAGR) of 6.9%. The escalation during this period is expected due to ongoing investigations for new applications, surges in healthcare spending, the need for non-injectable anemia treatments, improved reimbursement options, and an aging population. The significant trends predicted for this period are the move toward oral anemia remedies, mounting competition from substitute treatments, augmentation of licensing accords, increased funding in hypoxia-inducible factor studies, and prioritization of patient-focused therapeutic options._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Roxadustat Market?#_x000D_

The escalating prevalence of individuals suffering from chronic kidney disease (CKD) is anticipated to catalyze the expansion of the Roxadustat market in the future. CKD characterizes a long-term ailment where kidneys slowly lose their functionality, often escalating to kidney failure if not addressed timely. The global surge in people affected by CKD can be attributed to aging populations, a rise in diabetes and hypertension incidence, and unhealthy living habits. Roxadustat plays a crucial role in managing CKD by triggering the formation of erythropoietin, which boosts the production of red blood cells and mitigates the anemia often linked with the condition, thus enhancing overall kidney functioning and patient quality of life. For instance, a report released by the Australian Institute of Health and Welfare (AIHW), a government agency in Australia, in December 2024 indicated that mortality rates due to CKD witnessed a small annual increase, with a surge of 4.2% in 2021 and 6.2% in 2022. Hence, the escalating prevalence of CKD patients is fuelling the expansion of the Roxadustat market._x000D_

_x000D_

#Which Primary Segments of the Roxadustat Market Are Driving Growth and Industry Transformations?#_x000D_

The roxadustat market covered in this report is segmented – _x000D_

_x000D_

1) By Type: 20mg, 50mg_x000D_

2) By Product Formulation: Oral Tablets_x000D_

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers_x000D_

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Roxadustat Market?# Market?#_x000D_

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Roxadustat Market?#_x000D_

Prominent firms in the Roxadustat market are resorting to reimbursement through the high-tech drugs scheme, which ensures more extensive patient reach by eliminating financial hurdles, thus promoting market adoption and showcasing the cost-efficiency of their novel treatments. The high-tech drugs scheme, primarily operated by the government in Ireland, offers financial returns for the distribution of costly, highly specialized medicines typically suggested in hospital environments. For instance, in September 2022, US-based Astellas Pharma Company Ltd. declared that its drug EVRENZO (Roxadustat) obtained reimbursement under Ireland’s High-Tech Drugs Scheme. Roxadustat opens a new category of oral hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors that are licensed and reimbursed in Ireland. The outcomes revealed that Roxadustat was successful in achieving and sustaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, irrespective of dialysis status and previous ESA treatment._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Roxadustat Market?#_x000D_

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model